Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAINASDAQ:CLSDNASDAQ:PROKNASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Life Sciences$1.36-7.5%$1.73$1.03▼$2.85$269.70M1.181.54 million shs1.23 million shsCLSDClearside Biomedical$0.92-3.4%$0.96$0.77▼$1.65$69.62M2.1354,694 shs89,092 shsPROKProKidney$0.88-3.7%$1.33$0.86▼$4.44$266.36M1.38662,915 shs363,001 shsTERNTerns Pharmaceuticals$2.76-5.5%$3.90$2.77▼$11.40$240.94M-0.31.49 million shs1.06 million shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Life Sciences0.00%+1.38%-14.53%+8.89%-25.38%CLSDClearside Biomedical0.00%-5.47%+10.50%-4.50%-37.91%PROKProKidney0.00%-5.23%-26.02%-47.85%-44.51%TERNTerns Pharmaceuticals0.00%-12.84%-20.87%-47.20%-55.49%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATAIAtai Life Sciences3.3689 of 5 stars3.54.00.00.01.73.31.3CLSDClearside Biomedical2.299 of 5 stars3.54.00.00.01.81.70.0PROKProKidney2.0295 of 5 stars3.31.00.00.02.62.50.6TERNTerns Pharmaceuticals4.2909 of 5 stars3.33.00.04.12.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIAtai Life Sciences 3.00Buy$9.00561.76% UpsideCLSDClearside Biomedical 3.00Buy$5.25471.96% UpsidePROKProKidney 2.50Moderate Buy$5.00470.65% UpsideTERNTerns Pharmaceuticals 2.60Moderate Buy$18.38565.76% UpsideCurrent Analyst Ratings BreakdownLatest CLSD, ATAI, TERN, and PROK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/28/2025CLSDClearside BiomedicalChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/28/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.003/21/2025TERNTerns PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/19/2025ATAIAtai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/6/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/6/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.002/28/2025TERNTerns PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform2/13/2025ATAIAtai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.001/28/2025ATAIAtai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIAtai Life Sciences$308K875.64N/AN/A$1.47 per share0.93CLSDClearside Biomedical$7.70M9.04N/AN/A($0.25) per share-3.67PROKProKidney$76K3,374.50N/AN/A($4.84) per share-0.18TERNTerns PharmaceuticalsN/AN/AN/AN/A$4.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIAtai Life Sciences-$40.22M-$0.93N/AN/AN/AN/A-65.75%-52.71%5/21/2025 (Estimated)CLSDClearside Biomedical-$32.49M-$0.47N/AN/AN/A-413.83%N/A-92.90%5/7/2025 (Estimated)PROKProKidney-$35.47M-$0.63N/AN/AN/AN/AN/A-10.24%5/9/2025 (Estimated)TERNTerns Pharmaceuticals-$90.21M-$1.13N/AN/AN/AN/A-32.76%-31.33%5/12/2025 (Estimated)Latest CLSD, ATAI, TERN, and PROK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024CLSDClearside Biomedical-$0.13-$0.10+$0.03-$0.10$0.27 million$0.31 million3/20/2025Q4 2024TERNTerns Pharmaceuticals-$0.30-$0.24+$0.06-$0.24N/AN/A3/17/2025Q4 2024ATAIAtai Life Sciences-$0.14-$0.24-$0.10-$0.24$0.30 million($0.01) million3/17/2025Q4 2024PROKProKidney-$0.14-$0.17-$0.03-$0.17N/A$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATAIAtai Life SciencesN/AN/AN/AN/AN/ACLSDClearside BiomedicalN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIAtai Life Sciences0.145.815.81CLSDClearside BiomedicalN/A4.494.49PROKProKidneyN/A17.0817.09TERNTerns PharmaceuticalsN/A32.9932.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIAtai Life Sciences28.41%CLSDClearside Biomedical18.75%PROKProKidney51.59%TERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipATAIAtai Life Sciences31.20%CLSDClearside Biomedical9.20%PROKProKidney41.49%TERNTerns Pharmaceuticals15.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIAtai Life Sciences80198.31 million115.45 millionOptionableCLSDClearside Biomedical3075.84 million68.87 millionOptionablePROKProKidney3292.70 million170.65 millionOptionableTERNTerns Pharmaceuticals4087.30 million72.11 millionNot OptionableCLSD, ATAI, TERN, and PROK HeadlinesRecent News About These CompaniesAnalysts Set Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Target Price at $18.30March 28 at 1:19 AM | americanbankingnews.comAll You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to BuyMarch 26, 2025 | zacks.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMarch 25, 2025 | marketbeat.comOppenheimer Remains a Buy on Terns Pharmaceuticals (TERN)March 25, 2025 | markets.businessinsider.comTerns Pharmaceuticals' (TERN) Market Perform Rating Reiterated at William BlairMarch 24, 2025 | americanbankingnews.comWilliam Blair Reaffirms Market Perform Rating for Terns Pharmaceuticals (NASDAQ:TERN)March 22, 2025 | marketbeat.comWilliam Blair Reaffirms Their Hold Rating on Terns Pharmaceuticals (TERN)March 22, 2025 | markets.businessinsider.comTerns Pharmaceuticals Reports 2024 Progress and OutlookMarch 22, 2025 | tipranks.comTerns Pharmaceuticals (NASDAQ:TERN) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPSMarch 21, 2025 | marketbeat.comWhy Terns Pharmaceuticals, Inc.’s (TERN) Stock Is Up 14.97%March 21, 2025 | aaii.comTerns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate UpdatesMarch 20, 2025 | globenewswire.comThis Weight Loss Stock Could Skyrocket by 462%, According to Wall StreetMarch 9, 2025 | fool.comCandriam S.C.A. Buys New Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)March 8, 2025 | marketbeat.comTerns Pharmaceuticals (TERN) Projected to Post Quarterly Earnings on ThursdayMarch 6, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Rating of "Moderate Buy" by AnalystsMarch 1, 2025 | marketbeat.comWilliam Blair Initiates Coverage on Terns Pharmaceuticals (NASDAQ:TERN)March 1, 2025 | marketbeat.comTerns Pharmaceuticals initiated with a Market Perform at William BlairMarch 1, 2025 | markets.businessinsider.comWilliam Blair Initiates Coverage of Terns Pharmaceuticals (TERN) with Market Perform RecommendationMarch 1, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Vericel (VCEL) and Terns Pharmaceuticals (TERN)February 27, 2025 | markets.businessinsider.comIts CEO died. The company scrapped a promising program. Now, for their 2nd act.February 26, 2025 | finance.yahoo.comTerns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)February 26, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockSuper Micro's International Presence Makes It a Winning StockBy Gabriel Osorio-Mazilli | March 17, 2025View Super Micro's International Presence Makes It a Winning Stock3 Tech Stocks Defying Sector Weakness and Thriving in 2025By Leo Miller | March 10, 2025View 3 Tech Stocks Defying Sector Weakness and Thriving in 2025How to Build the Ultimate Everything ETF PortfolioBy Jeffrey Neal Johnson | March 16, 2025View How to Build the Ultimate Everything ETF PortfolioRobinhood's Rally: Is Global Expansion the Next Big Catalyst?By Leo Miller | March 6, 2025View Robinhood's Rally: Is Global Expansion the Next Big Catalyst?CLSD, ATAI, TERN, and PROK Company DescriptionsAtai Life Sciences NASDAQ:ATAI$1.36 -0.11 (-7.48%) Closing price 04:00 PM EasternExtended Trading$1.38 +0.01 (+1.10%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Clearside Biomedical NASDAQ:CLSD$0.92 -0.03 (-3.38%) Closing price 04:00 PM EasternExtended Trading$0.92 0.00 (-0.21%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.ProKidney NASDAQ:PROK$0.88 -0.03 (-3.71%) Closing price 04:00 PM EasternExtended Trading$0.88 +0.00 (+0.43%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Terns Pharmaceuticals NASDAQ:TERN$2.76 -0.16 (-5.48%) Closing price 04:00 PM EasternExtended Trading$2.78 +0.02 (+0.54%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Casey’s General Stores Insider Buys Shares of This Must-Own Stock U.S. Steel and Nippon Merger: Should Investors Bet on It? MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Lululemon Pulls Back Into Classic Dip-Buying Opportunity Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
